Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""CARDIOVASCULAR agents"" wg kryterium: Temat


Tytuł :
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
Autorzy :
Wallman M; Systems and Data Analysis, Fraunhofer-Chalmers Centre, Gothenburg, Sweden (M.W., M.J.); Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., E.M., N.P.); and Firma Biopharmacon, Gothenburg, Sweden (J.G.) .
Scheuerer S; Systems and Data Analysis, Fraunhofer-Chalmers Centre, Gothenburg, Sweden (M.W., M.J.); Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., E.M., N.P.); and Firma Biopharmacon, Gothenburg, Sweden (J.G.).
Martel E; Systems and Data Analysis, Fraunhofer-Chalmers Centre, Gothenburg, Sweden (M.W., M.J.); Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., E.M., N.P.); and Firma Biopharmacon, Gothenburg, Sweden (J.G.).
Pairet N; Systems and Data Analysis, Fraunhofer-Chalmers Centre, Gothenburg, Sweden (M.W., M.J.); Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., E.M., N.P.); and Firma Biopharmacon, Gothenburg, Sweden (J.G.).
Jirstrand M; Systems and Data Analysis, Fraunhofer-Chalmers Centre, Gothenburg, Sweden (M.W., M.J.); Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., E.M., N.P.); and Firma Biopharmacon, Gothenburg, Sweden (J.G.).
Gabrielsson J; Systems and Data Analysis, Fraunhofer-Chalmers Centre, Gothenburg, Sweden (M.W., M.J.); Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (S.S., E.M., N.P.); and Firma Biopharmacon, Gothenburg, Sweden (J.G.).
Pokaż więcej
Źródło :
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2021 May; Vol. 377 (2), pp. 218-231. Date of Electronic Publication: 2021 Mar 01.
Typ publikacji :
Journal Article
MeSH Terms :
Blood Pressure*
Heart Rate*
Biomarkers, Pharmacological/*blood
Cardiovascular Agents/*toxicity
Animals ; Cardiotoxicity/blood ; Cardiotoxicity/etiology ; Cardiotoxicity/physiopathology ; Cardiovascular Agents/administration & dosage ; Cardiovascular Agents/pharmacokinetics ; Ivabradine/administration & dosage ; Ivabradine/pharmacokinetics ; Ivabradine/toxicity ; Male ; Phenethylamines/administration & dosage ; Phenethylamines/pharmacokinetics ; Phenethylamines/toxicity ; Pyridazines/administration & dosage ; Pyridazines/pharmacokinetics ; Pyridazines/toxicity ; Rats ; Rats, Wistar ; Sildenafil Citrate/administration & dosage ; Sildenafil Citrate/pharmacokinetics ; Sildenafil Citrate/toxicity ; Sulfonamides/administration & dosage ; Sulfonamides/pharmacokinetics ; Sulfonamides/toxicity
Czasopismo naukowe
Tytuł :
Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study.
Autorzy :
Sun G; Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China.
Liu J; Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China.
Jia S; Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China.
Zhang J; Department of Vascular Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhuang B; Department of Peripheral Vascular Disease, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Jia X; Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China.
Fu W; Department of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Wu D; Department of Vascular Surgery, The People's Hospital of Liaoning Province, Shenyang, China.
Wang F; Department of Interventional Therapy, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhao Y; Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Guo P; Department of Vascular Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Bi W; Department of Vascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Wang S; Department of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Guo W; Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China.
Pokaż więcej
Corporate Authors :
AcoArt I Trial Investigators
Źródło :
Vascular [Vascular] 2021 Jun; Vol. 29 (3), pp. 340-349. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Coated Materials, Biocompatible*
Femoral Artery*/diagnostic imaging
Femoral Artery*/physiopathology
Popliteal Artery*/diagnostic imaging
Popliteal Artery*/physiopathology
Vascular Access Devices*
Angioplasty, Balloon/*instrumentation
Cardiovascular Agents/*administration & dosage
Peripheral Arterial Disease/*therapy
Aged ; Amputation ; Angioplasty, Balloon/adverse effects ; Angioplasty, Balloon/mortality ; Cardiovascular Agents/adverse effects ; China ; Chronic Disease ; Constriction, Pathologic ; Equipment Design ; Female ; Humans ; Limb Salvage ; Male ; Middle Aged ; Peripheral Arterial Disease/diagnostic imaging ; Peripheral Arterial Disease/mortality ; Peripheral Arterial Disease/physiopathology ; Recurrence ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Vascular Patency
Czasopismo naukowe
Tytuł :
Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
Autorzy :
Hamdani N; Institute of Physiology, Ruhr University, Bochum, Germany.; Molecular and Experimental Cardiology, Ruhr University, Bochum, Germany.; Department of Cardiology, St-Josef Hospital, Ruhr University, Bochum, Germany.; Clinical Pharmacology, Ruhr University, Bochum, Germany.
Costantino S; Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren CH-8952, Switzerland.
Mügge A; Molecular and Experimental Cardiology, Ruhr University, Bochum, Germany.; Department of Cardiology, St-Josef Hospital, Ruhr University, Bochum, Germany.
Lebeche D; Department of Medicine, Icahn School of Medicine at Mount Sinai, Cardiovascular Research Institute, New York, NY 10029, USA.; Department of Medicine, Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Department of Medicine, Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Tschöpe C; Berlin Institute of Health Center for Regenerative Therapies and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Berlin, Germany.; German Center for Cardiovascular Research (DZHK), Partner site Berlin, Berlin, Germany.; Department of Cardiology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK), Berlin, Germany.
Thum T; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.; REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.; Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover 30625, Germany.
Paneni F; Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren CH-8952, Switzerland.; University Heart Center, Cardiology, University Hospital Zurich, Zürich, Switzerland.; Department of Research and Education, University Hospital Zurich, Zürich, Switzerland.
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2021 May 21; Vol. 42 (20), pp. 1940-1958.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Cardiovascular Agents*/therapeutic use
Heart Failure*/drug therapy
Heart Failure*/genetics
Epigenesis, Genetic ; Female ; Humans ; Stroke Volume ; Ventricular Function, Left
Czasopismo naukowe
Tytuł :
Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
Autorzy :
Nicolaou PA; Department of Basic and Clinical Sciences, Medical School, University of Nicosia, Cyprus; Honorary Senior Lecturer, St. George's, University of London, UK. Electronic address: .
Pokaż więcej
Źródło :
European journal of pharmacology [Eur J Pharmacol] 2021 Apr 15; Vol. 897, pp. 173961. Date of Electronic Publication: 2021 Feb 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Cardiovascular Agents/*therapeutic use
Heart Failure/*drug therapy
Mineralocorticoid Receptor Antagonists/*therapeutic use
Renin-Angiotensin System/*drug effects
Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Cardiovascular Agents/adverse effects ; Female ; Health Status Disparities ; Healthcare Disparities ; Heart Failure/metabolism ; Heart Failure/physiopathology ; Humans ; Male ; Mineralocorticoid Receptor Antagonists/adverse effects ; Sex Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Biodegradable polymer-coated versus durable polymer-coated sirolimus-eluting stents: the final 5-year outcomes of the I-LOVE-IT 2 trial.
Autorzy :
Xu K; General Hospital of Northern Theater Command, Shenyang, China.
Xu B
Guan C
Jing Q
Zheng Q
Li X
Zhao X
Wang H
Zhao X
Li Y
Li J
Yang Y
Han Y
Pokaż więcej
Źródło :
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2021 Apr 02; Vol. 16 (18), pp. e1518-e1526. Date of Electronic Publication: 2021 Apr 02.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Cardiovascular Agents*/adverse effects
Coronary Artery Disease*/surgery
Drug-Eluting Stents*
Percutaneous Coronary Intervention*/adverse effects
Absorbable Implants ; Humans ; Polymers ; Risk Factors ; Sirolimus/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Long-Term Follow-Up of Percutaneous Coronary Intervention With Paclitaxel-Eluting Balloon Catheter.
Autorzy :
Sanchez-Perez I; Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.
Abellan-Huerta J; Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.
Jurado-Roman A; Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.
Lopez-Lluva MT; Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.
Pinilla-Echeverri N; 62703McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada.; Population Health Research Institute, Hamilton, Ontario, Canada.
Perez-Diaz P; Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.
Piqueras-Flores J; Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.
Lozano-Ruiz-Poveda F; Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.
Pokaż więcej
Źródło :
Angiology [Angiology] 2021 Apr; Vol. 72 (4), pp. 364-370. Date of Electronic Publication: 2020 Dec 17.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Cardiac Catheters*
Coated Materials, Biocompatible*
Acute Coronary Syndrome/*therapy
Angioplasty, Balloon, Coronary/*instrumentation
Cardiovascular Agents/*therapeutic use
Coronary Artery Disease/*therapy
Coronary Restenosis/*therapy
Paclitaxel/*therapeutic use
Acute Coronary Syndrome/diagnostic imaging ; Acute Coronary Syndrome/mortality ; Aged ; Angioplasty, Balloon, Coronary/adverse effects ; Angioplasty, Balloon, Coronary/mortality ; Cardiovascular Agents/adverse effects ; Coronary Artery Disease/diagnostic imaging ; Coronary Artery Disease/mortality ; Coronary Restenosis/diagnostic imaging ; Coronary Restenosis/mortality ; Equipment Design ; Female ; Humans ; Male ; Middle Aged ; Paclitaxel/adverse effects ; Prospective Studies ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Comparison of paclitaxel-coated balloon angioplasty with femoropopliteal bypass surgery in treating femoropopliteal lesions.
Autorzy :
Kavala AA; Department of Cardiovascular Surgery, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey.
Kuserli Y; Department of Cardiovascular Surgery, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey.
Turkyilmaz S; Department of Cardiovascular Surgery, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey.
Pokaż więcej
Źródło :
Vascular [Vascular] 2021 Apr; Vol. 29 (2), pp. 260-269. Date of Electronic Publication: 2020 Aug 24.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Blood Vessel Prosthesis Implantation*/adverse effects
Coated Materials, Biocompatible*
Vascular Access Devices*
Angioplasty, Balloon/*instrumentation
Cardiovascular Agents/*administration & dosage
Femoral Artery/*surgery
Intermittent Claudication/*therapy
Paclitaxel/*administration & dosage
Peripheral Arterial Disease/*therapy
Popliteal Artery/*surgery
Aged ; Angioplasty, Balloon/adverse effects ; Cardiovascular Agents/adverse effects ; Disease-Free Survival ; Equipment Design ; Female ; Femoral Artery/diagnostic imaging ; Femoral Artery/physiopathology ; Humans ; Intermittent Claudication/diagnostic imaging ; Intermittent Claudication/physiopathology ; Male ; Middle Aged ; Paclitaxel/adverse effects ; Peripheral Arterial Disease/diagnostic imaging ; Peripheral Arterial Disease/physiopathology ; Popliteal Artery/diagnostic imaging ; Popliteal Artery/physiopathology ; Retrospective Studies ; Time Factors ; Vascular Patency
Czasopismo naukowe
Tytuł :
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies.
Autorzy :
Xu S; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.) .
Ilyas I; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Little PJ; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Li H; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Kamato D; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Zheng X; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Luo S; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Li Z; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Liu P; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Han J; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Harding IC; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Ebong EE; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Cameron SJ; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Stewart AG; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.).
Weng J; Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China (S.X., I.I., X.Z., S.L., J.W.); Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Australia (P.J.L.); School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland, Australia (P.J.L., D.K.); Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China (H.L.); Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, National and Local United Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou, China (Z.L., P.L.); College of Life Sciences, Key Laboratory of Bioactive Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China (J.H.); Department of Bioengineering, Northeastern University, Boston, Massachusetts (I.C.H., E.E.E.); Department of Chemical Engineering, Northeastern University, Boston, Massachusetts (E.E.E.); Department of Neuroscience, Albert Einstein College of Medicine, New York, New York (E.E.E.); Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (S.J.C.); and ARC Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Science, University of Melbourne, Parkville, Victoria, Australia (A.G.S.) .
Pokaż więcej
Źródło :
Pharmacological reviews [Pharmacol Rev] 2021 Jul; Vol. 73 (3), pp. 924-967.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
MeSH Terms :
Atherosclerosis*/drug therapy
Atherosclerosis*/metabolism
Atherosclerosis*/physiopathology
COVID-19*/drug therapy
COVID-19*/metabolism
COVID-19*/physiopathology
Cardiovascular Agents*/classification
Cardiovascular Agents*/pharmacology
Cardiovascular Diseases*/drug therapy
Cardiovascular Diseases*/metabolism
Cardiovascular Diseases*/physiopathology
Endothelium, Vascular*/drug effects
Endothelium, Vascular*/metabolism
Endothelium, Vascular*/physiopathology
Drug Discovery ; Humans ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Comparison table: Some drugs for HFrEF.
Źródło :
The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2021 Mar 08; Vol. 63 (1619), pp. e1-e13. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cardiovascular Agents/*therapeutic use
Heart Failure/*drug therapy
Cardiovascular Agents/administration & dosage ; Cardiovascular Agents/adverse effects ; Cardiovascular Agents/economics ; Drug Interactions ; Humans ; Stroke Volume/physiology
Czasopismo naukowe
Tytuł :
Awareness and Knowledge Among Internal Medicine House-Staff for Dose Adjustment of Cardiovascular Drugs in Chronic Kidney Disease.
Autorzy :
D'Angelo K; Department of Cardiology, Nassau University Medical Center, East Meadow, NY, USA.
Paul S; Division of Nephrology and Hypertension, Department of Medicine, Nassau University Medical Center, 2201 Hempstead Turnpike, Box 49, East Meadow, NY, 11554, USA.
Ranjeeta F; Division of Nephrology and Hypertension, Department of Medicine, Nassau University Medical Center, 2201 Hempstead Turnpike, Box 49, East Meadow, NY, 11554, USA.
Fogel J; Department of Business Management, Brooklyn College, Brooklyn, NY, USA.
Chikvashvili D; Department of Cardiology, Nassau University Medical Center, East Meadow, NY, USA.
Rubinstein S; Division of Nephrology and Hypertension, Department of Medicine, Nassau University Medical Center, 2201 Hempstead Turnpike, Box 49, East Meadow, NY, 11554, USA. .
Pokaż więcej
Źródło :
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2021 Mar; Vol. 28 (2), pp. 177-184. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :
Journal Article
MeSH Terms :
Glomerular Filtration Rate*
Health Knowledge, Attitudes, Practice*
Internal Medicine*
Medical Staff, Hospital*
Cardiovascular Agents/*administration & dosage
Cardiovascular Diseases/*drug therapy
Kidney/*physiopathology
Renal Insufficiency, Chronic/*physiopathology
Adult ; Cardiovascular Agents/adverse effects ; Cardiovascular Diseases/complications ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/physiopathology ; Cross-Sectional Studies ; Drug Dosage Calculations ; Female ; Health Care Surveys ; Humans ; Male ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/diagnosis ; Risk Assessment ; Risk Factors
Czasopismo naukowe
Tytuł :
Effect of medications after cardiac surgery on long-term outcomes in patients with cirrhosis.
Autorzy :
Chou AH; Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou Medical, Center.; Collage of Medicine, Chang Gung University, Taoyuan City.
Lin YS; Department of Cardiology, Chiayi Branch, Chiayi City.
Wu VC; Department of Cardiology.
Chen FT; Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou Medical, Center.
Yang CH; Department of Cardiology.
Chen DY; Department of Cardiology.
Chen SW; Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center.; Graduate Institute of Clinical Medical Sciences, College of medicine, Chang Gung, University, Taoyuan City, Taiwan.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Feb 05; Vol. 100 (5), pp. e23075.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Cardiac Surgical Procedures/*statistics & numerical data
Cardiovascular Agents/*administration & dosage
Liver Cirrhosis/*epidemiology
Adrenergic beta-Antagonists/administration & dosage ; Adrenergic beta-Antagonists/adverse effects ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/administration & dosage ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/administration & dosage ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Cardiovascular Agents/adverse effects ; Cardiovascular Agents/classification ; Female ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Male ; Middle Aged ; Renal Insufficiency/epidemiology ; Taiwan/epidemiology
Czasopismo naukowe
Tytuł :
Ivabradine effects on heart rate and quality of life among chronic heart failure patients.
Autorzy :
Farooq F; Department of Cardiology, National Institute of Cardiovascular Diseases, Karachi, Pakistan.
Imran N; National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan.
Abbas M; National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan.
Pokaż więcej
Źródło :
JPMA. The Journal of the Pakistan Medical Association [J Pak Med Assoc] 2021 Jan; Vol. 71 (1(A)), pp. 86-89.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Cardiovascular Agents*/pharmacology
Cardiovascular Agents*/therapeutic use
Heart Failure*/drug therapy
Adult ; Aged ; Benzazepines/pharmacology ; Benzazepines/therapeutic use ; Female ; Heart Rate ; Humans ; Ivabradine/pharmacology ; Ivabradine/therapeutic use ; Male ; Middle Aged ; Quality of Life ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions.
Autorzy :
Kelbæk H; Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.
Yeh RW
Engstrøm T
Neumann FJ
Serruys PW
Windecker S
Belardi J
Qiao S
Xu B
Liu M
Silber S
Pokaż więcej
Źródło :
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2021 Mar 19; Vol. 16 (16), pp. 1326-1332.
Typ publikacji :
Journal Article
MeSH Terms :
Cardiovascular Agents*
Coronary Artery Disease*
Coronary Occlusion*/surgery
Drug-Eluting Stents*
Myocardial Infarction*
Percutaneous Coronary Intervention*/adverse effects
China/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Prosthesis Design ; Sirolimus/analogs & derivatives ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact of public health emergency response to COVID-19 on management and outcome for NSTEMI patients in Beijing: A single-center historic control.
Autorzy :
Liu S; Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Beijing, China.
Song C; Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Beijing, China.
Yin D; Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Beijing, China.
Wang Y; Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Beijing, China.
Zhao Y; Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Beijing, China.
Yang W; Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Beijing, China.
Qiao S; Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Beijing, China.
Dou K; Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Beijing, China.
Xu B; Catheterization Laboratories, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło :
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2021 Mar; Vol. 97 (4), pp. E475-E483. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*
Cardiology Service, Hospital/*trends
Cardiovascular Agents/*therapeutic use
Coronary Artery Bypass/*trends
Emergency Service, Hospital/*trends
Non-ST Elevated Myocardial Infarction/*therapy
Percutaneous Coronary Intervention/*trends
Public Health/*trends
Aged ; Beijing ; Cardiovascular Agents/adverse effects ; Coronary Artery Bypass/adverse effects ; Coronary Artery Bypass/mortality ; Female ; Heart Failure/etiology ; Hospital Mortality/trends ; Humans ; Male ; Middle Aged ; Non-ST Elevated Myocardial Infarction/complications ; Non-ST Elevated Myocardial Infarction/diagnosis ; Non-ST Elevated Myocardial Infarction/mortality ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/mortality ; Recurrence ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care.
Autorzy :
Ibanez B; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.; Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain.; CIBERCV, Madrid, Spain.
Roque D; Cardiology Department, Prof. Dr. Fernando Fonseca Hospital, Amadora, Portugal.
Price S; Department of Cardiology and Department of Adult Critical Care, Royal Brompton Hospital, London, UK.
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2021 Mar 01; Vol. 42 (9), pp. 884-895.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Acute Coronary Syndrome*/drug therapy
Cardiovascular Agents*/therapeutic use
Myocardial Infarction*/drug therapy
Heart ; Humans
Czasopismo naukowe
Tytuł :
Consensus of experts from the French Society of Geriatrics and Gerontology on the management of heart failure in very old subjects.
Autorzy :
Hanon O; Service de gériatrie, hôpital Broca, AP-HP, 75013 Paris, France; EA 4468, gérontopôle d'Île-de-France, université de Paris, 75013 Paris, France. Electronic address: .
Belmin J; Service de gériatrie, hôpital Charles-Foix, 94200 Ivry-sur-Seine, France; Faculté de médecine, Sorbonne université, 75103 Paris, France.
Benetos A; Service de médecine interne gériatrique, CHRU plurithématiques-Nancy, 54035 Nancy, France; UMR_S 1116, Inserm, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.
Chassagne P; Service de médecine interne gériatrique, CHU de Rouen, 76000 Rouen, France.
De Decker L; Service de gérontologie clinique, CHU de Nantes, 44093 Nantes, France.
Jeandel C; Centre Antonin-Balmès, CHU de Montpellier, 34090 Montpellier, France.
Krolak-Salmon P; Institut du vieillissement, hôpital des Charpennes, hospices civils de Lyon, 69002 Lyon, France; Inserm 1048, université de Lyon, 69675 Bron, France.
Nourhashemi F; Gérontopôle, CHU de Toulouse, 31059 Toulouse, France; Inserm 1027, 31000 Toulouse, France.
Paccalin M; Pôle de Gériatrie, CHU La Milétrie, 86021 Poitiers, France; CIC 1402, Inserm, centre hospitalier universitaire de Poitiers, université de Poitiers, 86000 Poitiers, France.
Pokaż więcej
Źródło :
Archives of cardiovascular diseases [Arch Cardiovasc Dis] 2021 Mar; Vol. 114 (3), pp. 246-259. Date of Electronic Publication: 2021 Jan 14.
Typ publikacji :
Journal Article; Practice Guideline; Review
MeSH Terms :
Palliative Care*
Cardiology/*standards
Cardiovascular Agents/*therapeutic use
Geriatrics/*standards
Heart Failure/*drug therapy
Age Factors ; Aged, 80 and over ; Cardiovascular Agents/adverse effects ; Clinical Decision-Making ; Comorbidity ; Consensus ; Decision Support Techniques ; Female ; Frail Elderly ; Health Status ; Heart Failure/diagnosis ; Heart Failure/mortality ; Heart Failure/physiopathology ; Humans ; Male ; Prevalence ; Quality of Life ; Recovery of Function ; Risk Assessment ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[The safety and efficacy of Firesorb bioresorbable scaffold in first-in-man study for coronary artery disease: the four-year outcomes].
Autorzy :
Li CJ; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Xu B; Catheter Lab, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Song L; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Yu MY; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Yan HB; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Qiu H; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Mu CW; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Cui JG; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Guan CD; Catheter Lab, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Sun ZW; Catheter Lab, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Qiao SB; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Gao RL; Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
Pokaż więcej
Źródło :
Zhonghua xin xue guan bing za zhi [Zhonghua Xin Xue Guan Bing Za Zhi] 2021 Feb 24; Vol. 49 (2), pp. 128-135.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Cardiovascular Agents*
Coronary Artery Disease*/diagnostic imaging
Coronary Artery Disease*/surgery
Drug-Eluting Stents*
Percutaneous Coronary Intervention*
Absorbable Implants ; Humans ; Male ; Middle Aged ; Prospective Studies ; Sirolimus ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Five-year clinical outcomes of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary lesions].
Autorzy :
Wang G; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Na K; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Li Y; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Jing QM; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Wang XZ; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Liu HW; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Wang B; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Xu K; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Han YL; Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Pokaż więcej
Źródło :
Zhonghua xin xue guan bing za zhi [Zhonghua Xin Xue Guan Bing Za Zhi] 2021 Feb 24; Vol. 49 (2), pp. 121-127.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Cardiovascular Agents*
Coronary Artery Disease*/surgery
Drug-Eluting Stents*
Percutaneous Coronary Intervention*
Aged ; China ; Humans ; Male ; Middle Aged ; Polymers ; Risk Factors ; Sirolimus/therapeutic use ; Time Factors ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies